Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation

Hirosuke Yamaji, Takashi Murakami, Kazuyoshi Hina, Shunichi Higashiya, Hiroshi Kawamura, Masaaki Murakami, Shigeshi Kamikawa, Satoshi Hirohata, Shozo Kusachi

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. Objectives: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. Method: Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. Results: Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups. Conclusion: Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.

Original languageEnglish
Pages (from-to)409-418
Number of pages10
JournalClinical Drug Investigation
Volume33
Issue number6
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Atrial Fibrillation
Warfarin
Therapeutics
Cardiac Tamponade
Stroke
Dabigatran
Safety
Pericardial Effusion
Groin
Transient Ischemic Attack
Complementary Therapies
Pulmonary Embolism
Venous Thrombosis
Hematoma
Anticoagulants
Heparin
Cardiac Arrhythmias
Kidney
Incidence

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Yamaji, H., Murakami, T., Hina, K., Higashiya, S., Kawamura, H., Murakami, M., ... Kusachi, S. (2013). Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. Clinical Drug Investigation, 33(6), 409-418. https://doi.org/10.1007/s40261-013-0081-1

Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. / Yamaji, Hirosuke; Murakami, Takashi; Hina, Kazuyoshi; Higashiya, Shunichi; Kawamura, Hiroshi; Murakami, Masaaki; Kamikawa, Shigeshi; Hirohata, Satoshi; Kusachi, Shozo.

In: Clinical Drug Investigation, Vol. 33, No. 6, 06.2013, p. 409-418.

Research output: Contribution to journalArticle

Yamaji, H, Murakami, T, Hina, K, Higashiya, S, Kawamura, H, Murakami, M, Kamikawa, S, Hirohata, S & Kusachi, S 2013, 'Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation', Clinical Drug Investigation, vol. 33, no. 6, pp. 409-418. https://doi.org/10.1007/s40261-013-0081-1
Yamaji, Hirosuke ; Murakami, Takashi ; Hina, Kazuyoshi ; Higashiya, Shunichi ; Kawamura, Hiroshi ; Murakami, Masaaki ; Kamikawa, Shigeshi ; Hirohata, Satoshi ; Kusachi, Shozo. / Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation. In: Clinical Drug Investigation. 2013 ; Vol. 33, No. 6. pp. 409-418.
@article{1acef6f54da3422da4090352dde37bc8,
title = "Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation",
abstract = "Background: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. Objectives: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. Method: Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. Results: Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 {\%}) and Group 2 (2/203, 0.98 {\%}) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 {\%}) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 {\%} and 2/194, 1.0 {\%}; Group 2: 3/203, 1.5 {\%} and 2/203, 1.0 {\%}, respectively). As a whole, the safety outcomes did not differ among the three groups. Conclusion: Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.",
author = "Hirosuke Yamaji and Takashi Murakami and Kazuyoshi Hina and Shunichi Higashiya and Hiroshi Kawamura and Masaaki Murakami and Shigeshi Kamikawa and Satoshi Hirohata and Shozo Kusachi",
year = "2013",
month = "6",
doi = "10.1007/s40261-013-0081-1",
language = "English",
volume = "33",
pages = "409--418",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "6",

}

TY - JOUR

T1 - Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation

AU - Yamaji, Hirosuke

AU - Murakami, Takashi

AU - Hina, Kazuyoshi

AU - Higashiya, Shunichi

AU - Kawamura, Hiroshi

AU - Murakami, Masaaki

AU - Kamikawa, Shigeshi

AU - Hirohata, Satoshi

AU - Kusachi, Shozo

PY - 2013/6

Y1 - 2013/6

N2 - Background: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. Objectives: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. Method: Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. Results: Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups. Conclusion: Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.

AB - Background: The usefulness of dabigatran etexilate for the prevention of stroke in patients with atrial fibrillation (AF) has been reported. Objectives: In this study the efficacy and safety of dabigatran etexilate for anticoagulation for AF ablation were examined. Method: Patients were divided into three groups: Group 1, interrupted warfarin bridged by heparin between pre- and post-ablation; Group 2, continuous warfarin therapy; and Group 3, dabigatran etexilate therapy. Anticoagulation therapy with warfarin or dabigatran etexilate was performed from 30 days before to at least 90 days after AF ablation. Dabigatran etexilate was administered at 110 or 150 mg twice daily, depending on renal function and age. Results: Patients' clinical characteristics, associated disorders, echocardiographic parameters and arrhythmia status were not different among the three groups. Procedural parameters such as procedural time and radiofrequency energy supply were also not different among the three groups. The dabigatran etexilate group and the warfarin groups had no embolic complications (stroke, cerebral transient ischaemic attack, deep venous thrombosis or pulmonary embolism). No pericardial tamponade was observed in the dabigatran etexilate group, while two patients in each of Group 1 (2/194, 1.0 %) and Group 2 (2/203, 0.98 %) developed cardiac tamponade, though the differences were not significant. Pericardial effusion and groin haematoma were observed in one patient each (1/105, 0.9 %) in the dabigatran etexilate group, and the incidences were not different from the warfarin group (Group 1: 4/194, 2.1 % and 2/194, 1.0 %; Group 2: 3/203, 1.5 % and 2/203, 1.0 %, respectively). As a whole, the safety outcomes did not differ among the three groups. Conclusion: Dabigatran etexilate is an effective and safe anticoagulation therapy for AF ablation. Thus, dabigatran etexilate appears to be useful as an alternative anticoagulant therapy to warfarin for AF ablation.

UR - http://www.scopus.com/inward/record.url?scp=84878702358&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878702358&partnerID=8YFLogxK

U2 - 10.1007/s40261-013-0081-1

DO - 10.1007/s40261-013-0081-1

M3 - Article

C2 - 23572324

AN - SCOPUS:84878702358

VL - 33

SP - 409

EP - 418

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 6

ER -